Survey on knowledge and attitudes about GATTEX use
Quantitative Testing of Patient and Prescriber Knowledge About GATTEX (Teduglutide) for Injection Safety and Use Information
This study is trying to understand what patients and doctors know and think about using GATTEX to treat Short Bowel Syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Takeda Industry-sponsored |
| Locations | 1 site (Cambridge, Massachusetts) |
| Trial ID | NCT05561647 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the knowledge, attitudes, and behaviors of participants and physicians regarding the use of GATTEX for treating Short Bowel Syndrome. Participants who have taken GATTEX within the last 60 days will complete a survey, which can be conducted via internet, telephone, or paper, based on their preference. Healthcare providers who have prescribed GATTEX are also invited to participate in the survey. The study does not involve any medication interventions.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have used GATTEX in the past 60 days.
Not a fit: Patients who have not used GATTEX or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of GATTEX usage, leading to improved patient care and safety.
How similar studies have performed: While this study focuses on knowledge and attitudes, similar surveys in other therapeutic areas have shown success in improving treatment understanding and adherence.
Eligibility criteria
Show full inclusion / exclusion criteria
Participant inclusion criteria: Participants who are 18 years of age and who have taken GATTEX in the 60 days prior to survey implementation are eligible to participate in the survey. A caregiver may participate in this survey on behalf of a participant who is eligible but unable to complete the survey. Note: Participants who have previously participated in a GATTEX Patient Knowledge Assessment Survey, are eligible. Prescriber inclusion criteria: HCPs (adult and pediatric) in the United States who can provide a 10-digit National Provider Identifier (NPI) number and who have prescribed GATTEX at least once regardless of their completion of the voluntary GATTEX REMS training (Prescriber Education Slide Deck) are eligible for participation in the survey. Note: HCPs who have previously participated in a GATTEX Prescriber Knowledge Assessment Survey, are eligible Participant and Prescriber exclusion criteria: * Respondents who do not agree to participate in the survey. * Respondents who are currently working for and/or whose immediate family members who are currently working for Takeda Pharmaceuticals U.S.A., Inc., NPS Pharmaceuticals, Inc., Shire, UBC, or the Food and Drug Administration (FDA) are not eligible to participate in the survey. * Respondents who reported having a conflict of interest. * HCPs who have opted out of receiving communications about the GATTEX Prescriber Knowledge Assessment Survey for the current wave Further details associated with respondents who do not meet the exclusion criteria established above, will be provided in the assessment report.
Where this trial is running
Cambridge, Massachusetts
- Takeda Pharmaceuticals, U.S.A., Inc. — Cambridge, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Takeda Contact
- Email: medinfoUS@takeda.com
- Phone: +1-877-825-3327
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.